

Mingzhou Guo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6915236/publications.pdf>

Version: 2024-02-01

107
papers

5,002
citations

94433

37
h-index

106344

65
g-index

111
all docs

111
docs citations

111
times ranked

7083
citing authors

#	ARTICLE	IF	CITATIONS
1	CpG Site-Specific Methylation-Modulated Divergent Expression of PRSS3 Transcript Variants Facilitates Nongenetic Intratumor Heterogeneity in Human Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 831268.	2.8	2
2	BCL6B hypermethylation predicts metastasis and poor prognosis in early-stage hepatocellular carcinoma after thermal ablation. <i>Journal of Cancer Research and Therapeutics</i> , 2021, 17, 644.	0.9	1
3	Methylation of NRN1 is a novel synthetic lethal marker of PI3K-Akt-mTOR and ATR inhibitors in esophageal cancer. <i>Cancer Science</i> , 2021, 112, 2870-2883.	3.9	18
4	Downregulation of the FTO m6A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors. <i>Nature Cancer</i> , 2021, 2, 611-628.	13.2	30
5	Intratumor Epigenetic Heterogeneity—A Panel Gene Methylation Study in Thyroid Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 714071.	2.3	4
6	Methylation of <i>TMEM176A</i> , a key ERK signaling regulator, is a novel synthetic lethality marker of ATM inhibitors in human lung cancer. <i>Epigenomics</i> , 2021, 13, 1403-1419.	2.1	8
7	Aberrant NSUN2-mediated m5C modification of H19 lncRNA is associated with poor differentiation of hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 6906-6919.	5.9	131
8	Epigenetic based synthetic lethal strategies in human cancers. <i>Biomarker Research</i> , 2020, 8, 44.	6.8	19
9	Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. <i>Cancer Science</i> , 2020, 111, 3111-3121.	3.9	43
10	Changes of the Gastric Mucosal Microbiome Associated With Histological Stages of Gastric Carcinogenesis. <i>Frontiers in Microbiology</i> , 2020, 11, 997.	3.5	75
11	Methylation silencing of TGF- β 2 receptor type II is involved in malignant transformation of esophageal squamous cell carcinoma. <i>Clinical Epigenetics</i> , 2020, 12, 25.	4.1	14
12	Epigenetic silencing of IGF2BP1 promotes esophageal cancer growth by activating PI3K-AKT signaling. <i>Clinical Epigenetics</i> , 2020, 12, 22.	4.1	19
13	Epigenetic heterogeneity in cancer. <i>Biomarker Research</i> , 2019, 7, 23.	6.8	145
14	HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer. <i>Scientific Reports</i> , 2019, 9, 12628.	3.3	48
15	MicroRNA-31 Reduces Inflammatory Signaling and Promotes Regeneration in Colon Epithelium, and Delivery of Mimics in Microspheres Reduces Colitis in Mice. <i>Gastroenterology</i> , 2019, 156, 2281-2296.e6.	1.3	140
16	Loss of BAP1 Results in Growth Inhibition and Enhances Mesenchymal-Epithelial Transition in Kidney Tumor Cells. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1320-1329.	3.8	20
17	Methylation of SLFN11 promotes gastric cancer growth and increases gastric cancer cell resistance to cisplatin. <i>Journal of Cancer</i> , 2019, 10, 6124-6134.	2.5	14
18	Phase Ib/II study of safety and efficacy of low-dose decitabine-primed chemoimmunotherapy in patients with drug-resistant relapsed/refractory alimentary tract cancer. <i>International Journal of Cancer</i> , 2018, 143, 1530-1540.	5.1	21

#	ARTICLE	IF	CITATIONS
19	Epigenetic silencing of TMEM176A activates ERK signaling in human hepatocellular carcinoma. <i>Clinical Epigenetics</i> , 2018, 10, 137.	4.1	21
20	Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer. <i>Clinical Epigenetics</i> , 2018, 10, 69.	4.1	21
21	DNA methylation-mediated repression of miR-181a/135a/302c expression promotes the microsatellite-unstable colorectal cancer development and 5-FU resistance via targeting PLAG1. <i>Journal of Genetics and Genomics</i> , 2018, 45, 205-214.	3.9	30
22	Synthesis of 5 β ,8 β -Ergosterol Peroxide 3 β -Carbamate Derivatives and a Fluorescent Mitochondria α -Targeting Conjugate for Enhanced Anticancer Activities. <i>ChemMedChem</i> , 2017, 12, 466-474.	3.2	20
23	Recurrently deregulated lncRNAs in hepatocellular carcinoma. <i>Nature Communications</i> , 2017, 8, 14421.	12.8	279
24	Methylation of <i>SLFN11</i> is a marker of poor prognosis and cisplatin resistance in colorectal cancer. <i>Epigenomics</i> , 2017, 9, 849-862.	2.1	55
25	Methylation of DACT2 promotes breast cancer development by activating Wnt signaling. <i>Scientific Reports</i> , 2017, 7, 3325.	3.3	17
26	The safety, efficacy, and treatment outcomes of a combination of low-dose decitabine treatment in patients with recurrent ovarian cancer. <i>Oncolmmunology</i> , 2017, 6, e1323619.	4.6	23
27	Synthesis and biological evaluation of novel steroidal 5 β ,8 β -epidioxyandrost-6-ene-3 β -ol-17-(O-phenylacetamide)oxime derivatives as potential anticancer agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3856-3861.	2.2	17
28	Meeting Report of the Fifth International Cancer Epigenetics Conference in Beijing, China, October 2016. <i>Epigenomics</i> , 2017, 9, 937-941.	2.1	0
29	Synthesis and biological evaluation of novel steroidal 5 β ,8 β -endoperoxide derivatives with aliphatic side-chain as potential anticancer agents. <i>Steroids</i> , 2017, 124, 46-53.	1.8	21
30	Epigenetic silencing of PRSS3 provides growth and metastasis advantage for human hepatocellular carcinoma. <i>Journal of Molecular Medicine</i> , 2017, 95, 1237-1249.	3.9	15
31	Methylation of <i>TMEM176A</i> is an independent prognostic marker and is involved in human colorectal cancer development. <i>Epigenetics</i> , 2017, 12, 575-583.	2.7	28
32	Methylation of DIRAS1 promotes colorectal cancer progression and may serve as a marker for poor prognosis. <i>Clinical Epigenetics</i> , 2017, 9, 50.	4.1	25
33	Genetic and Methylation-Induced Loss of miR-181a2/181b2 within chr9q33.3 Facilitates Tumor Growth of Cervical Cancer through the PIK3R3/Akt/FoxO Signaling Pathway. <i>Clinical Cancer Research</i> , 2017, 23, 575-586.	7.0	28
34	Methylation of ZNF331 is an independent prognostic marker of colorectal cancer and promotes colorectal cancer growth. <i>Clinical Epigenetics</i> , 2017, 9, 115.	4.1	32
35	Silencing HOXD10 by promoter region hypermethylation activates ERK signaling in hepatocellular carcinoma. <i>Clinical Epigenetics</i> , 2017, 9, 116.	4.1	33
36	ZNF545 suppresses human hepatocellular carcinoma growth by inhibiting NF-kB signaling. <i>Genes and Cancer</i> , 2017, 8, 528-535.	1.9	11

#	ARTICLE	IF	CITATIONS
37	Epigenetic silencing of TMEM176A promotes esophageal squamous cell cancer development. <i>Oncotarget</i> , 2017, 8, 70035-70048.	1.8	22
38	Epigenetic regulation of voltage-gated potassium ion channel molecule Kv1.3 in mechanisms of colorectal cancer. <i>Discovery Medicine</i> , 2017, 23, 155-162.	0.5	10
39	Methylation of <i>DACT2</i> accelerates esophageal cancer development by activating Wnt signaling. <i>Oncotarget</i> , 2016, 7, 17957-17969.	1.8	26
40	The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer. <i>Oncotarget</i> , 2016, 7, 37331-37346.	1.8	73
41	LncRNA MT1JP functions as a tumor suppressor by interacting with TIAR to modulate the p53 pathway. <i>Oncotarget</i> , 2016, 7, 15787-15800.	1.8	59
42	Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1912-1926.	1.1	38
43	C ₆₀ (OH) ₂₂ : a potential histone deacetylase inhibitor with anti-angiogenic activity. <i>Nanoscale</i> , 2016, 8, 16332-16339.	5.6	12
44	Portraying breast cancers with long noncoding RNAs. <i>Science Advances</i> , 2016, 2, e1600220.	10.3	102
45	Design, synthesis, and biological activity of 4-(imidazo[1,2- b]pyridazin-3-yl)-1 H -pyrazol-1-yl-phenylbenzamide derivatives as BCRâ€ABL kinase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 5830-5835.	2.2	9
46	The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. <i>Clinical Epigenetics</i> , 2016, 8, 43.	4.1	74
47	Epigenetic Upregulation of Metallothionein 2A by Diallyl Trisulfide Enhances Chemosensitivity of Human Gastric Cancer Cells to Docetaxel Through Attenuating NF-ÎB Activation. <i>Antioxidants and Redox Signaling</i> , 2016, 24, 839-854.	5.4	53
48	Epigenome-based personalized medicine in human cancer. <i>Epigenomics</i> , 2016, 8, 119-133.	2.1	76
49	Transcriptional profiling analysis and functional prediction of long noncoding RNAs in cancer. <i>Oncotarget</i> , 2016, 7, 8131-8142.	1.8	49
50	Systematic study of novel lncRNAs in different gastrointestinal cancer cells. <i>Discovery Medicine</i> , 2016, 21, 159-71.	0.5	9
51	Expression profiling and functional prediction of long noncoding RNAs in nasopharyngeal nonkeratinizing carcinoma. <i>Discovery Medicine</i> , 2016, 21, 239-50.	0.5	8
52	Epigenetic changes and functional study of <i>HOXA11</i> in human gastric cancer. <i>Epigenomics</i> , 2015, 7, 201-213.	2.1	40
53	Methylation-induced loss of <i>miR-484</i> in microsatellite-unstable colorectal cancer promotes both viability and <i>IL-8</i> production via <i>CD137L</i> . <i>Journal of Pathology</i> , 2015, 236, 165-174.	4.5	37
54	Functional Characterization of Long Noncoding RNA Lnc_bc060912 in Human Lung Carcinoma Cells. <i>Biochemistry</i> , 2015, 54, 2895-2902.	2.5	29

#	ARTICLE	IF	CITATIONS
55	Hypermethylation of ZNF545 is associated with poor prognosis in patients with early-stage hepatocellular carcinoma after thermal ablation: Table 1. <i>Gut</i> , 2015, 64, 1836-1837.	12.1	9
56	Predictive value of CHFR and MLH1 methylation in human gastric cancer. <i>Gastric Cancer</i> , 2015, 18, 280-287.	5.3	63
57	Epigenetics of Colorectal Cancer. <i>Methods in Molecular Biology</i> , 2015, 1238, 405-424.	0.9	17
58	Epigenetics of Gastric Cancer. <i>Methods in Molecular Biology</i> , 2015, 1238, 783-799.	0.9	22
59	RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker. <i>Genes and Cancer</i> , 2015, 6, 231-240.	1.9	18
60	RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel. <i>Oncotarget</i> , 2015, 6, 4202-4213.	1.8	19
61	DACH1 is a novel predictive and prognostic biomarker in hepatocellular carcinoma as a negative regulator of Wnt/ β -catenin signaling. <i>Oncotarget</i> , 2015, 6, 8621-8634.	1.8	42
62	Epigenetic silencing of BCL6B inactivates p53 signaling and causes human hepatocellular carcinoma cell resist to 5-FU. <i>Oncotarget</i> , 2015, 6, 11547-11560.	1.8	31
63	DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. <i>Oncotarget</i> , 2015, 6, 5877-5888.	1.8	40
64	Epigenetic silencing of NKD2, a major component of Wnt signaling, promotes breast cancer growth. <i>Oncotarget</i> , 2015, 6, 22126-22138.	1.8	29
65	Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancer. <i>Oncotarget</i> , 2015, 6, 33470-33485.	1.8	26
66	Silencing GPX3 Expression Promotes Tumor Metastasis in Human Thyroid Cancer. <i>Current Protein and Peptide Science</i> , 2015, 16, 316-321.	1.4	56
67	Methylation of ZNF331 Promotes Cell Invasion and Migration in Human Esophageal Cancer. <i>Current Protein and Peptide Science</i> , 2015, 16, 322-328.	1.4	17
68	Epigenetic silencing BCL6B induced colorectal cancer proliferation and metastasis by inhibiting P53 signaling. <i>American Journal of Cancer Research</i> , 2015, 5, 651-62.	1.4	15
69	CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancer. <i>Discovery Medicine</i> , 2015, 19, 151-8.	0.5	13
70	Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer. <i>Discovery Medicine</i> , 2015, 20, 261-71.	0.5	3
71	Silencing DACH1 Promotes Esophageal Cancer Growth by Inhibiting TGF- β Signaling. <i>PLoS ONE</i> , 2014, 9, e95509.	2.5	26
72	DACH1 inhibits cyclin D1 expression, cellular proliferation and tumor growth of renal cancer cells. <i>Journal of Hematology and Oncology</i> , 2014, 7, 73.	17.0	54

#	ARTICLE	IF	CITATIONS
73	Epigenetic silencing of <i>DACH1</i> induces the invasion and metastasis of gastric cancer by activating <i>TGFβ2</i> signalling. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 2499-2511.	3.6	34
74	Clinical and pathological features of miR-10b and RHOC gene expression in hepatocellular carcinoma. <i>Science Bulletin</i> , 2014, 59, 2249-2253.	1.7	3
75	Amplification of the miR-181c/d cluster is inversely correlated with PDCD4 expression in gastric cancer. <i>Science Bulletin</i> , 2014, 59, 2240-2248.	1.7	3
76	Methylation of DACT2 Promotes Papillary Thyroid Cancer Metastasis by Activating Wnt Signaling. <i>PLoS ONE</i> , 2014, 9, e112336.	2.5	29
77	Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel. <i>Genes and Cancer</i> , 2014, 6, 38-48.	1.9	27
78	Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas. <i>Discovery Medicine</i> , 2014, 17, 67-73.	0.5	29
79	DACT2 is frequently methylated in human gastric cancer and methylation of DACT2 activated Wnt signaling. <i>American Journal of Cancer Research</i> , 2014, 4, 710-24.	1.4	26
80	Epigenetic silencing of RASSF10 promotes tumor growth in esophageal squamous cell carcinoma. <i>Discovery Medicine</i> , 2014, 17, 169-78.	0.5	16
81	Spatially graded segregation and recovery of circulating tumor cells from peripheral blood of cancer patients. <i>Biomicrofluidics</i> , 2013, 7, 34109.	2.4	31
82	Epigenetic regulation of DACT2, a key component of the Wnt signalling pathway in human lung cancer. <i>Journal of Pathology</i> , 2013, 230, 194-204.	4.5	52
83	Epigenetic silencing of DACH1 induces loss of transforming growth factor- β 1 antiproliferative response in human hepatocellular carcinoma. <i>Hepatology</i> , 2013, 58, 2012-2022.	7.3	56
84	Epigenetic regulation of <i>DACH1</i> , a novel Wnt signaling component in colorectal cancer. <i>Epigenetics</i> , 2013, 8, 1373-1383.	2.7	79
85	Epigenetic regulation of the Wnt signaling inhibitor <i>DACT2</i> in human hepatocellular carcinoma. <i>Epigenetics</i> , 2013, 8, 373-382.	2.7	33
86	Epigenetic silencing of CXCL14 induced colorectal cancer migration and invasion. <i>Discovery Medicine</i> , 2013, 16, 137-47.	0.5	31
87	CDX2 serves as a Wnt signaling inhibitor and is frequently methylated in lung cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 1152-1157.	3.4	16
88	Methylation of <i>TFPI-2</i> is an early event of esophageal carcinogenesis. <i>Epigenomics</i> , 2012, 4, 135-146.	2.1	43
89	Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 577-585.	2.8	58
90	AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer. <i>Tumor Biology</i> , 2012, 33, 307-314.	1.8	19

#	ARTICLE	IF	CITATIONS
91	A Facile and Specific Assay for Quantifying MicroRNA by an Optimized RT-qPCR Approach. PLoS ONE, 2012, 7, e46890.	2.5	74
92	SOX17 antagonizes WNT/ β 2-catenin signaling pathway in hepatocellular carcinoma. Epigenetics, 2010, 5, 743-749.	2.7	122
93	DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer. New England Journal of Medicine, 2008, 358, 1118-1128.	27.0	546
94	Promoter methylation of <i>HIN-1</i> in the progression to esophageal squamous cancer. Epigenetics, 2008, 3, 336-341.	2.7	43
95	Evaluation of GATA-4 and GATA-5 methylation profiles in human pancreatic cancers indicate promoter methylation patterns distinct from other human tumor types. Cancer Biology and Therapy, 2007, 6, 1546-1552.	3.4	33
96	Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. International Journal of Cancer, 2007, 121, 1219-1226.	5.1	39
97	Ca ²⁺ Channel Expression in Human Esophageal Carcinomas: A Functional Role in Proliferation. FASEB Journal, 2007, 21, A538.	0.5	0
98	a-catenin Hypermethylation Correlates with AML Transformation in Patients with and without 5q Defects.. Blood, 2007, 110, 2119-2119.	1.4	0
99	Hypermethylation of the GATA gene family in esophageal cancer. International Journal of Cancer, 2006, 119, 2078-2083.	5.1	54
100	Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biology and Therapy, 2006, 5, 152-155.	3.4	27
101	Gefitinib-Sensitizing Mutations in Esophageal Carcinoma. New England Journal of Medicine, 2006, 354, 2193-2194.	27.0	47
102	Accumulation of Promoter Methylation Suggests Epigenetic Progression in Squamous Cell Carcinoma of the Esophagus. Clinical Cancer Research, 2006, 12, 4515-4522.	7.0	104
103	Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Modern Pathology, 2005, 18, 412-420.	5.5	128
104	Hypermethylation of the GATA Genes in Lung Cancer. Clinical Cancer Research, 2004, 10, 7917-7924.	7.0	117
105	Promoter Hypermethylation of Resected Bronchial Margins. Clinical Cancer Research, 2004, 10, 5131-5136.	7.0	156
106	Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis, 2003, 24, 193-198.	2.8	146
107	Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Research, 2002, 62, 5902-5.	0.9	118